Nicholas Hornstein/X
May 17, 2025, 21:36
Nicholas Hornstein: New FDA Approval for Metastatic Anal Cancer
Nicholas Hornstein, Assistant Professor at Northwell Health, shared on X:
“New FDA approval for metastatic anal cancer.
Retifanlimab + Carbo-Pac brings anti-PDL1 into the front-line metastatic setting.
mOS 29 vs 23 months
ORR 56% vs 44%Based off POD1UM-303. Great randomized study in a rare disease!”
An impactful article on Anal Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 7, 2025, 17:41
Jun 7, 2025, 16:47
Jun 7, 2025, 16:40
Jun 7, 2025, 16:30
Jun 7, 2025, 16:07
Jun 7, 2025, 15:49